US Patent
US12509443 — CSF-1R inhibitors and methods of use thereof
Formulation · Assigned to Deciphera Pharmaceuticals LLC · Expires 2045-04-30 · 19y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a pharmaceutical composition containing a compound of Formula (I) or its hydrate, essentially free of impurities, and methods of use thereof.
USPTO Abstract
Provided herein, in part, is a compound of Formula (I) or a hydrate thereof, essentially free of one or more impurities, compositions thereof, and methods of use thereof.
Drugs covered by this patent
- Romvimza (VIMSELTINIB) · Deciphera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.